Adverse Events (AD1) Web Version: 1.0; 5.00; 07-26-12 Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM): The following AEs do not require reporting in the data system: Grade 1 (mild) and Grade 2 (moderate) Unrelated Events. 1. Adverse event name: (A1DESCRI) 2. Date site became aware of the event: (A1AWARDT) (mm/dd/yyyy) Click here to view calendar 3. Severity of event: (A 1SEVEVE) 1-Grade 1 - Mild 2-Grade 2 - Moderate 3-Grade 3 - Severe 4-Grade 4 - Life-threatening 5-Grade 5-Death 4. Relationship to study intervention: (A1RELTB) 1-Unrelated 2-Possibly related 3-Probably related 4-Definitely related If "Unrelated" to study intervention, alternative etiology:(A 1ALTEB) O-None apparent 1-S tudy disease 2-Concomitant medication 3-O ther pre-existing disease or condition 4-Accident, trauma, or external factors *Additional Options Listed Below If "Other," specify: (A1AEBSP) 5. Action taken with study intervention: (A1ACTBI) 0-None 1-Decreased intervention 2-Increased intervention 3-T emporarily stopped intervention 4-Permanentlystopped intervention *Additional Options Listed Below

6. Outcome of event: (A1OUTCM)	1-Ongoing 2-Resolved without sequelae 3-Resolved with sequelae 4-Resolved by convention 5-Death	
7. Date of resolution or medically stable: (A1RESDT)	(mm/dd/yyyy)	
Except for "None of the following" and "Hospitalization for a medical event", all selections in the question below will designate this as a Serious Adverse Event (SAE). The Serious Adverse Event Summary (AD2) form should be completed for all Serious Adverse Events reported.		

8. Was this event associated with: <i>(A1ASSOCI)</i>	O-None of the following 1O-Hospitalization for a medical event 1-Death 2-Life-threatening event 3-Inpatient admission to hospital *Additional Options Listed Below
If "Death", date of death: (A1DTHDTE)	(mm/dd/yyyy)
9. If "Inpatient admission to hospital" or "Prolongation of hospitalization": Date of hospital admission: (A1HOSPAD)	(mm/dd/yyyy)
Date of hospital discharge: (A1HOSPDC)	(mm/dd/yyyy)
Comments: (A1COMM)	

Investigator's Signature

I have reviewed all the data recorded on all CRF pages associated with this Adverse Event, as well as any associated documentation, and certify that they are accurate and complete to the best of my knowledge.

Principal Investigator or designee: (A1PISIGN)	
Date:(A1PISGDT)	(mm/dd/yyyy)

MedDRA:

The following fields are auto-populated by the DSC2 based on MedDRA coding of the Adverse Event name. Preferred Term: (MEDRAPT)

System Organ Class: (MEDRASOC)

Not Coded

Additional Selection Options for AD1

Select Sequence Number (AESEQNUM) (key field):

01-1st Adverse E vent of the day 02-2nd Adverse E vent of the day 03-3rd Adverse E vent of the day 04-4th Adverse E vent of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day

Action taken with study intervention: 5-Participant terminated from study

Was this event associated with:

4-Prolon gation of hospitalization

5-Persistent or significant disability or incapacity

6-Congenital anomaly or birth defect

- 7-Required significant intervention to prevent permanent impairment or damage
- 9-Important medical event

Serious Adverse Event Summary (AD2)

Web Version: 1.0; 1.00; 03-09-12

Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM):

1. Initial narrative description of serious adverse event:



2. Relevant Past Medical History: (A2SAEMHX) No Yes Unknown Allergies, pregnancy, smoking and alcohol use, hypertension, diabetes, epilepsy, depression, etc.

(A2 MEDHX)	

3. Medications at the Time of the Event: (A2SAEMED) 🗌 No 👘 Yes 🗍 Unknown

Medication (Generic Name)	Indication
(A2_01DNM)	(A2_01DIN)
(A2_02DNM)	(A2_02DIN)
(A2_03DNM)	(A2_03DIN)
(A2_04DNM)	(A2_04DIN)
(A2_05DNM)	(A2_05DIN)

(A2_06DNM)	(A2_06DIN)
(A2_07DNM)	(A2_07DIN)
(A2_08DNM)	(A2_08DIN)
(A2_09DNM)	(A2_09DIN)
(A2_10DNM)	(A2_10DIN)

4. Treatments for the Event: (A2SAETRT) 🗌 No 👘 Yes 👘 Unknown

Treatment	Indication	Date T reated
(A2_1 TNME)	(A2_1 TIND)	(A2_1LTDT) (mm/dd/yyyy)
(A2_2 TNME)	(A2_2 TIND)	(A2_2LTDT) (mm/dd/yyyy)
(A2_3TNME)	(A2_3TIND)	(A2_3LTDT) (mm/dd/yyyy)
(A2_4 TNME)	(A2_4TIND)	(A2_4LTDT) (mm/dd/yyyy)
(A2_5TNME)	(A2_5TIND)	(A2_5LTDT) (mm/dd/yyyy)

^{5.} Labs/Tests Performed in Conjunction with this Event: (A2SAELAB) 🗌 No 👘 Yes 👘 Unknown

Lab/T est	Findings	Date of Test	
(A2_1LBNM)	(A2_1LBIN)	(A2_1LBDT) (mm/dd/yyyy)	
(A2_2LBNM)	(A2_2LBIN)	(A2_2LBDT) (mm/dd/yyyy)	
(A2_3LBNM)	(A2_3LBIN)	(A2_3LBDT) (mm/dd/yyyy)	
(A2_4LBNM)	(A2_4LBIN)	(A2_4LBDT) (mm/dd/yyyy)	
(A2_5LBNM)	(A2_5LBIN)	(A2_5LBDT) (mm/dd/yyyy)	

6. Follow-Up:

Include labs/test results as they become available, clinical changes, consultant diagnosis, etc.

(A2 FOLLUP)	

7. Additional information requested by the Medical Monitor:



(A2 ADDINF

Have all Medical Monitor requests been addressed?(A2RQADDR)

C Yes

Additional Selection Options for AD2

Select Sequence Number (AESEQNUM) (key field): 01-1st Adverse Event of the day

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Serious Adverse Event Medical Reviewer (AD3)

Web Version: 1.0; 3.00; 03-09-12


Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM):

1. Was this determined to be a serious adverse event? (A3DETER)	□ No	Yes
2. Was this event considered associated with the study's behavioral intervention? (A3BHINT)	No No	Yes
3. Was this event expected? (A3EXPECT)	🗌 No	Yes
4. Is this a standard expedited/reportable event? (i.e., is it serious, unexpected and related to therapy) (A3EXPFDA)	□ No	Yes
5. Is this an expedited/reportable event for other reasons? (A3EXPOTH)	□ No	Yes
6. Does the protocol need to be modified based on this event? (A3EXPDSM)	□ No	Yes
7. Does the consent form need to be modified based on this event? (A3CONSEN)	🗆 No	Yes
8. Is the review complete?(A3REVDNE)	□ No	Yes
If "No", what additional information is required:(A3ADDINF)		

Assessed by:(A2ASRID) Reviewed by:(A3REVID)

Comments: (A3COMM)

Robert Lindblad
 Radhika Kondapaka
 Robert Lindblad



Additional Selection Options for AD3

Select Sequence Number (AESEQNUM) (key field): 01-1st Adverse Event of the day

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Adverse Event (AE1) Web Version: 1.0: 2.00: 08-27-12 Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM): The following AEs do not require reporting in the data system: Grade 1 (mild) and Grade 2 (moderate) Unrelated Events. 1. Adverse event name: (A1DESCRI) 2. Date site became aware of the event: (A1AWARDT) (mm/dd/yyyy) 3. Severity of event: (A 1SEVEVE) 1-Grade 1 - Mild 2-Grade 2 - Moderate 3-Grade 3 - Severe 4-Grade 4 - Life-threatening 5-Grade 5-Death 4. Relationship to study intervention: (A1RELTB) 1-Unrelated 2-Possibly related 3-Probably related 4-Definitely related If "Unrelated" to study intervention, alternative etiology:(A 1ALTEB) O-None apparent 1-S tudy disease 2-Concomitant medication 3-O ther pre-existing disease or condition 4-Accident, trauma, or external factors *Additional Options Listed Below If "Other," specify: (A1AEBSP) 5. Action taken with study intervention: (A1ACTBI) 0-None 1-Decreased intervention 2-Increased intervention 3-T emporarily stopped intervention 4-Permanentlystopped intervention *Additional Options Listed Below

6. Outcome of event: (A1OUTCM)	1-Ongoing 2-Resolved without sequelae 3-Resolved with sequelae 4-Resolved by convention 5-Death
7. Date of resolution or medically stable: (A1RESDT)	(mm/dd/yyyy)
Exact for "None of the following" all calestions in the question below will design to this as a Se	views Advarsa Evant (SAE). The Serious Advarsa Evant Summery (AD2) form should be completed for all Serious Advarsa

Except for "None of the following", all selections in the question below will designate this as a Serious Adverse Event (SAE). The Serious Adverse Event Summary (AD2) form should be completed for all Serious Adverse Events reported.

8. Was this event associated with: <i>(A1ASSOCI)</i>	O-None of the following 10-Hospitalization for a medical event 1-Death 2-Life-threatening event 3-Inpatient admission to hospital *Additional Options Listed Below
If "Death", date of death: (A1DTHDTE)	(mm/dd/yyyy)
9. If "Inpatient admission to hospital" or "Prolongation of hospitalization": Date of hospital admission: (A1HOSPAD)	(mm/dd/yyyy)
Date of hospital discharge: (A1HOSPDC)	(mm/dd/yyyy)
Comments: (A1COMM)	

Investigator's Signature

I have reviewed all the data recorded on all CRF pages associated with this Adverse Event, as well as any associated documentation, and certify that they are accurate and complete to the best of my knowledge.

Principal Investigator or designee: (A1PISIGN)	
Date:(A1PISGDT)	(mm/dd/yyyy)

MedDRA:

The following fields are auto-populated by the DSC2 based on MedDRA coding of the Adverse Event name. Preferred Term: (MEDRAPT)

System Organ Class: (MEDRASOC)

Not Coded

Additional Selection Options for AE1

Select Sequence Number (AESEQNUM) (key field):

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Action taken with study intervention: 5-Participant terminated from study

Was this event associated with:

4-Prolon gation of hospitalization

5-Persistent or significant disability or incapacity

6-Congenital anomaly or birth defect

- 7-Required significant intervention to prevent permanent impairment or damage
- 9-Important medical event

Serious Adverse Event Summary (AE2)

Web Version: 1.0; 1.00; 08-30-10

Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM):

1. Initial narrative description of serious adverse event:



2. Relevant Past Medical History: (A2SAEMHX) No Yes Unknown Allergies, pregnancy, smoking and alcohol use, hypertension, diabetes, epilepsy, depression, etc.

(A2 MEDHX)	

3. Medications at the Time of the Event: (A2SAEMED) 🗌 No 🗌 Yes 🗌 Unknown

Medication (Generic Name)	Indication
(A2_01DNM)	(A2_01DIN)
(A2_02DNM)	(A2_02DIN)
(A2_03DNM)	(A2_03DIN)
(A2_04DNM)	(A2_04DIN)
(A2_05DNM)	(A2_05DIN)

(A2_06DNM)	(A2_06DIN)
(A2_07DNM)	(A2_07DIN)
(A2_08DNM)	(A2_08DIN)
(A2_09DNM)	(A2_09DIN)
(A2_10DNM)	(A2_10DIN)

4. Treatments for the Event: (A2SAETRT) 🗌 No 👘 Yes 👘 Unknown

Treatment	Indication	Date T reated
(A2_1 TNME)	(A2_1 TIND)	(A2_1LTDT) (mm/dd/yyyy)
(A2_2 TNME)	(A2_2 TIND)	(A2_2LTDT) (mm/dd/yyyy)
(A2_3TNME)	(A2_3TIND)	(A2_3LTDT) (mm/dd/yyyy)
(A2_4 TNME)	(A2_4TIND)	(A2_4LTDT) (mm/dd/yyyy)
(A2_5TNME)	(A2_5TIND)	(A2_5LTDT) (mm/dd/yyyy)

^{5.} Labs/Tests Performed in Conjunction with this Event: (A2SAELAB) 🗌 No 👘 Yes 👘 Unknown

Lab/T est	Findings	Date of Test
(A2_1LBNM)	(A2_1LBIN)	(A2_1LBDT) (mm/dd/yyyy)
(A2_2LBNM)	(A2_2LBIN)	(A2_2LBDT) (mm/dd/yyyy)
(A2_3LBNM)	(A2_3LBIN)	(A2_3LBDT) (mm/dd/yyyy)
(A2_4LBNM)	(A2_4LBIN)	(A2_4LBDT) (mm/dd/yyyy)
(A2_5LBNM)	(A2_5LBIN)	(A2_5LBDT) (mm/dd/yyyy)

6. Follow-Up:

Include labs/test results as they become available, clinical changes, consultant diagnosis, etc.

(A2 FOLLUP)	

7. Additional information requested by the Medical Monitor:



(A2 ADDINF

Have all Medical Monitor requests been addressed?(A2RQADDR)

C Yes

Additional Selection Options for AE2

Select Sequence Number (AESEQNUM) (key field): 01-1st Adverse Event of the day

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Serious Adverse Event Medical Reviewer (AE3)

Web Version: 1.0; 1.01; 10-28-10

Adverse Event Onset Date (AEDATE): Select Sequence Number (AESEQNUM):

1. Was this determined to be a serious adverse event? (A3DETER)	🗌 No	Yes
2. Was this event considered associated with the study's behavioral intervention? (A3BHINT)	🗌 No	Yes
3. Was this event expected? (A3EXPECT)	□ No	Yes
4. Is this a standard expedited/reportable event? (i.e., is it serious, unexpected and related to therapy) (A3EXPFDA)	□ No	Yes
5. Is this an expedited/reportable event for other reasons? (A3EXPOTH)	□ No	Yes
6. Does the protocol need to be modified based on this event?(A3EXPDSM)	□ No	Yes
7. Does the consent form need to be modified based on this event? (A3CONSEN)	□ No	Yes
8. Is the review complete?(A3REVDNE)	🗌 No	Yes
If "No", what additional information is required:(A3ADDINF)		
IF "NO", what additional information is required:(<i>A3ADDIINF)</i>		

Assessed by:(A2ASRID) Reviewed by:(A3REVID)

Comments: (A3COMM)

Robert Lindblad
 Radhika Kondapaka
 Robert Lindblad



Additional Selection Options for AE3

Select Sequence Number (AESEQNUM) (key field): 01-1st Adverse Event of the day

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Brief Intervention Checklist (BIC)

Web Version: 1.0; 1.00; 09-08-10

Date of assessment: (BICASMDT) (mm/dd/yyyy) Click here to view calendar 1. Structuring statement and agenda setting:(BICSTRUC) □ No □ Yes Notes: (BICSTRNT) 🗌 No 🗌 Yes 2. Open motivational interviewing: (BICOMI) Notes: (BICOMINT) 3. Gives personalized feedback:(BICGVPFB) No Yes Notes: (BICP FBNT)


No Yes



5. Discusses action plan:(BICAP)

Notes: (BICA PNT)


□ No □ Yes



6. Closes on good terms:(BICENDOK) Notes:(BICENDNT)

Comments: (BICCOMM)

No Yes



Booster Center Tracking Log (BKT)

Web Version: 1.0; 1.00; 02-27-12

Segment (PROTSEG): Visit Number (VISNO):

D	ate	Time (in minutes)	Staff ID
1. (BK01DT)	(mm/dd/yyyy) Calendar	(BK01TM) (xxx)	(BK01ID) (xxxxx)
2. (BK02DT)	(mm/dd/yyyy) Calendar	(BK02TM) (xxx)	(BK021D) (xxxxx)
3. (BK03DT)	(mm/dd/yyyy) Calendar	(BK03TM) (xxx)	(BK03ID) (xxxxx)
4. (BK04DT)	(mm/dd/yyyy) Calendar	(BK04TM) (xxx)	(BK04ID) (xxxxx)
5. (BK05DT)	(mm/dd/yyyy) Calendar	(BK05TM) (xxx)	(BK05ID) (xxxxx)
6. (BK06DT)	(mm/dd/yyyy) Calendar	(BK06TM) (xxx)	(BK06ID) (xxxxx)
7. (BK07DT)	(mm/dd/yyyy) Calendar	(BK07TM) (xxx)	(BK07ID) (xxxxx)
8. (BK08DT)	(mm/dd/yyyy) Calendar	(BK08TM) (xxx)	(BK08ID) (xxxxx)
9. (BK09DT)	(mm/dd/yyyy) Calendar	(BK09TM) (xxx)	(BK09ID) (xxxxx)
10. (BK10DT)	(mm/dd/yyyy) Calendar	(BK10TM) (xxx)	(BK10ID) (XXXXX)

Date		Time (in minutes)		Staff ID	
11. (BK11DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK11TM) (2	xxx)	(BK11ID)	(xxxxx)
12. (BK12DT)	(mm/dd/yyyy) Calendar	(BK12TM) (2	xxx)	(BK12ID)	(xxxxx)
13. <i>(BK13DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK13TM) (2	xxx)	(BK13ID)	(xxxxx)
14. (<i>BK14DT</i>)	(mm/dd/yyyy) Calendar	(BK14TM) (2	xxx)	(BK14ID)	(xxxxx)
15. <i>(BK15DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK15TM) (2	xxx)	(BK15ID)	(xxxxx)
16. <i>(BK16DT)</i>	(mm/dd/yyyy) Calendar	(BK16TM) (2	xxx)	(BK16ID)	(xxxxx)
17. (<i>BK17DT</i>)	(mm/dd/yyyy) <u>Calendar</u>	(BK17TM) (2	xxx)	(BK17ID)	(xxxxx)
18. <i>(BK18DT)</i>	(mm/dd/yyyy) Calendar	(BK18TM) (2	xxx)	(BK18ID)	(xxxxx)
19. <i>(BK19DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(ВК19ТМ) (2	xxx)	(BK19ID)	(xxxxx)
20. (BK20DT)	(mm/dd/yyyy) Calendar	(ВК20ТМ) (2	xxx)	(BK20ID)	(xxxxx)

Date)	Time (in minutes)	Staff ID
21. <i>(BK21DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK21TM) (xxx)	(BK211D) (xxxxx)
22. (BK22DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK22TM) (xxx)	(BK221D) (xxxxx)
23. (BK23DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK23TM) (xxx)	(BK23ID) (xxxxx)
24. (BK24DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK24TM) (xxx)	(BK24ID) (xxxxx)
25. (BK25DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK25TM) (xxx)	(BK25ID) (xxxxx)
26. (BK26DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK26TM) (xxx)	(BK26ID) (xxxxx)
27. (BK27DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK27TM) (xxx)	(BK27ID) (xxxxx)
28. (BK28DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK28TM) (xxx)	(BK28ID) (xxxxx)
29. <i>(BK29DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK29TM) (xxx)	(BK29ID) (xxxxx)
30. (BK30DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK30TM) (xxx)	(BK30ID) (xxxxx)

I	Date	Time (in minutes)	Staff ID
31. <i>(BK31DT)</i>	(mm/dd/yyyy) Calendar	(BK31TM) (xxx)	(BK311D) (xxxxx)
32. (BK32DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK32TM) (xxx)	(BK321D) (XXXXX)
33. (BK33DT)	(mm/dd/yyyy) Calendar	(BK33TM) (xxx)	(BK33ID) (xxxxx)
34. (BK34DT)	(mm/dd/yyyy) Calendar	(BK34TM) (xxx)	(BK34ID) (XXXXX)
35. <i>(BK35DT)</i>	(mm/dd/yyyy) Calendar	(BK35TM) (xxx)	(BK35ID) (XXXXX)
36. (BK36DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK36TM) (xxx)	(BK36ID) (xxxxx)
37. (BK37DT)	(mm/dd/yyyy) Calendar	(BK37TM) (xxx)	(BK37ID) (xxxxx)
38. (BK38DT)	(mm/dd/yyyy) Calendar	(BK38TM) (xxx)	(BK38ID) (xxxxx)
39. <i>(BK39DT)</i>	(mm/dd/yyyy) Calendar	(BK39TM) (xxx)	(BK39ID) (xxxxx)
40. (BK40DT)	(mm/dd/yyyy) Calendar	(BK40TM) (xxx)	(BK40ID) (xxxxx)

Date	Time (in minutes)	Staff ID
41. (BK41DT) (mm/dd/yyyy) <u>Calendar</u>	(BK41TM) (xxx)	(BK411D) (XXXXX)
42. (BK42DT) (mm/dd/yyyy) Calendar	(BK42TM) (xxx)	(BK421D) (xxxxx)
43. (BK43DT) (mm/dd/yyyy) <u>Calendar</u>	(BK43TM) (xxx)	(BK43ID) (xxxxx)

44. (BK44DT) (mm/dd/yyyy) <u>Calendar</u>	(BK44TM) (xxx)	(BK44ID) (xxxxx)
45. (BK45DT) (mm/dd/yyyy) <u>Calendar</u>	(BK45TM) (xxx)	(BK45ID) (xxxxx)
46. (BK46DT) (mm/dd/yyyy) <u>Calendar</u>	(BK46TM) (xxx)	(BK46ID) (xxxxx)
47. (BK47DT) (mm/dd/yyyy) <u>Calendar</u>	(BK47TM) (xxx)	(BK47ID) (xxxxx)
48. (BK48DT) (mm/dd/yyyy) <u>Calendar</u>	(BK48TM) (xxx)	(BK48ID) (xxxxx)
49. (BK49DT) (mm/dd/yyyy) <u>Calendar</u>	(BK49TM) (xxx)	(BK49ID) (xxxxx)
50. (BK50DT) (mm/dd/yyyy) <u>Calendar</u>	(BK50TM) (xxx)	(BK50ID) (xxxxx)

Date)	Time (in minutes)	Staff ID
51. <i>(BK51DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK51TM) (xxx)	(BK51ID) (XXXXX)
52. (BK52DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK52TM) (xxx)	(BK52ID) (XXXXX)
53. (BK53DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK53TM) (xxx)	(BK53ID) (xxxxx)
54. (BK54DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK54TM) (xxx)	(BKR54ID) (xxxxx)
55. (BK55DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK55TM) (xxx)	(BK55ID) (XXXXX)
56. (BK56DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK56TM) (xxx)	(BK56ID) (XXXXX)
57. (BK57DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK57TM) (xxx)	(BK57ID) (xxxxx)
58. (BK58DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK58TM) (xxx)	(BK58ID) (xxxxx)
59. (BK59DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK59TM) (xxx)	(BK59ID) (XXXXX)
60. (BK60DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK60TM) (xxx)	(BK60ID) (XXXXX)

Date	Time (in minutes)	Staff ID
61. (BK61DT) (mm/dd/yyyy) <u>Calendar</u>	(BK61TM) (xxx)	(BK61ID) (xxxxx)
62. (BK62DT) (mm/dd/yyyy) <u>Calendar</u>	(BK62TM) (xxx)	(BK621D) (xxxxx)
63. (BK63DT) (mm/dd/yyyy) <u>Calendar</u>	(BK63TM) (xxx)	(BK63ID) (xxxxx)
64. (BK64DT) (mm/dd/yyyy) <u>Calendar</u>	(BK64TM) (xxx)	(BK64ID) (xxxxx)
65. (BK65DT) (mm/dd/yyyy) <u>Calendar</u>	(BK65TM) (xxx)	(BK65ID) (xxxxx)
66. (BK66DT) (mm/dd/yyyy) Calendar	(BK66TM) (xxx)	(BK661D) (xxxxx)
67. (BK67DT) (mm/dd/yyyy) <u>Calendar</u>	(BK67TM) (xxx)	(BK67ID) (xxxxx)
68. (BK68DT) (mm/dd/yyyy) <u>Calendar</u>	(BK68TM) (xxx)	(BK68ID) (xxxxx)

69. <i>(BK69DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(BK69TM) (xxx)	(BK69ID) (xxxxx)
70. (BK70DT)	(mm/dd/yyyy) <u>Calendar</u>	(BK70TM) (xxx)	(BK70ID) (XXXXX)

Comments: (BKTCOMM)

Booster Intervention Checklist (BOC)


Web Version: 1.0; 2.00; 10-04-10

Booster Visit (BOCVST):

Date of assessment: (BOCASMDT)

1. Structuring statement and agenda setting:(BOCSTRUC)

Notes: (BOCSTRNT)



2. Open motivational interviewing: (BOCOM I)

Notes: (BOCOM INT)

3. Discusses action plan:(BOCAP) Notes:(BOCAPNT)

No Yes




🗌 No 🗌 Yes



Notes: (BOCENDNT)

Comments: (BOCCOMM)



Additional Selection Options for BOC

Booster Visit (*BOCVST*) (key field): 01-01 02-02

Booster Record Form (BRF)

Segment (PROTSEG): Visit Number (VISNO):

Date of assessment: (BRASMDT) 1. Was this session initiated?(BRSESINI)	(mm/dd/yyyy) <u>Click here to view calendar</u>
If session not initiated, select reason: (BRREASON)	1-Unreachable at close of assessment window 2-Refused 3-Deceased 4-Unavailable 5-O ther
lf "Other", specify: (BROTHRSP)	
2. Time Start: (BRTMSTRT)	(hh:mm)
Time End: <i>(BRTMEEND)</i>	(hh:mm)
3. Was this session interrupted? (BRINTRPD)	O-No 1-Yes
If "Yes", total length of interruption(s): <i>(BRTIMEIP)</i>	(xxxx) minutes
4. Were you able to complete the session? (BRSESCOM)	O-No 1-Yes

Web Version: 1.0; 2.00; 07-26-11

lf "No", specify: <i>(BRNOSP)</i>		
If "Yes", did the session resume on the same day?(<i>BRSAMEDY</i>) If "No", what was the date that it	No	Yes (mm/dd/yyyy) Click here for calendar
was completed? (BRSES2DT)		
lf "No", explain: <i>(BRNOSAME)</i>		
5. Was the session recorded? (BRSESREC)	No No	Yes
If "Yes", upload	the audi	o file using the link at the bottom of this form.

(xx) (min)

6. What was the total session time as indicated by the a udio file (round up to whole minute)? (BRAUDIO)

Personal Rulers Worksheet

Importance Ruler:

0 Not at all important	1	2 Somewhat important	3	4 Fairly important	5	6 Important	7	8 Very important	9	10 Extremely important
(BRIMPRUL)										

Confidence Ruler:

0 Not at all confident	1	2 Somewhat con fide nt	3	4 Fairly confident	5	6 Confident	7	8 Very confident	9	10 E xtre mely confiden t
(BRCONRUL)										

Readiness Ruler:

0 Not at all ready	1	2 Somewhat ready	3	4 Fairly ready	5	6 Ready	7	8 Very ready	9	10 Completely ready
(BRREDRUL)										

Summary of session: (BRSESSUM)	
(

Barriers to Treatment Inventory (BTI)

Segment (PROTSEG): Visit Number (VISNO):

Date of assessment: (BTASMDT)

(mm/dd/yyyy) Click here to view calendar

Please respond to each of the statements below by indicating how much you AGREE or DISAGREE with each one. Mark only one choice for each statement. Thank you for your participation.

	Disa gree S tro ngly	Disagree	Uncertain	Agree	Agree Strongly
1. I do not think I have a problem with drugs.	(BTPRBME)				
2. No one has told me I have a problem with drugs.	(BTPRBYOU)				
3. My drug use is not causing any problems.	(BTNOPROB)				
4. I do not think treatment will make my life better.	(BTTXLIFE)				
5. I can handle my drug use on my own.	(BTDRGOWN)				
6. I do not think I need treatment.	(BTNOTX)				
7. I will lose my friends if I go to treatment.	(BTLOSEFR)				
8. Friends tell me not to go to treatment.	(BTFRNOTX)				
9. People will think badly of me if I go to treatment.	(BTBADTX)				
10. Someone in my family does not want me to go to treatment.	(BTFAMNO)				
11. My family will be embarrassed or a shamed if I go to treatment.	(BTEMBFAM)				
12. I have had a bad experience with treatment.	(BTBADEXP)				
13. I am afraid of what might happen in treatment.	(BTAFRAID)				
14. I am afraid of the people I might see in treatment.	(BTAFRPLE)				
15. I am too embarrassed or ashamed to go to treatment.	(BTASHAME)				
16. I do not like to talk in groups.	(BTNOTALK)				
17. I hate being a sked personal questions.	(BTPERQS)				
18. I do not like to talk about my personal life with other people.	(BTPERTLK)				
19. I have things to do at home that make it hard for me to get to treatment.	(BTHOMETX)				
20. It will be hard for me to find a treatment program that fits my schedule.	(втѕснтх) 🗆				


Web Version: 1.0; 1.00; 07-02-10

21. I am moving too far away to get treatment.	(BTFARTX)		
22. I do not know where to go for treatment.	(BTLOCTX)		
23. I have difficulty getting to and from treatment.	(BTTRANTX)		
24. I will have to be on a waiting list for treatment.	(BTWAITTX)		
25. I have to go through too many steps to get into treatment.	(BTSTEPTX)		
26. I have difficulty finding child care.	(BTCHLDTX)		
27. I am afraid of losing custody of my child(ren).	(BTCUSTDY)		
28. I am afraid of child protective services becoming involved.	(BTCHLDPS)		

Assessment completed by:(BTCOMPLT)

Research Assistant Participant

Comments: (BTICOMM)



Additional Demographics (DM2)

Web Version: 1.0; 1.00; 09-03-10

Segment (PROTSEG): Visit Number (VISNO):



Answer the following question to represent the majority of the last 3 years, not just the most recent selection. If there are equal times for more than one category, select that which best represents the more current situation. 3. Usual Employment Pattern in past 3 years; (ADEMP3 YR)

1-Full Time (35+ hrs/wk) 2-Part Time (regular hrs) 3-Part Time (irregular hrs, day-work) 4-Student 5-In Controlled Environment 6-Service 7-Retired/Disability 8-Homemaker 9-Unemployed

Answer the following question to represent the majority of the last 30 days, not just the most recent selection. If there are equal times for more than one category, select that which best represents the more current situation.

4. Usual Employment Pattern in past 30 days: (ADEMP30D)

1-Full Time (35+ hrs/wk) 2-Part Time (regular hrs) 3-Part Time (irregular hrs, day-work) 4-S tudent 5-In Controlled Environment 6-Service 7-Retired/Disability 8-Homemaker 9-Unemployed 5. Annual Household Income: (ADINCOME)

Comments: (ADMCOMM)

1-\$0-\$15,000 2-\$15,001-\$30,000 3-\$30,001-\$50,000 4-\$50,001-\$75,000 5-\$75,001-\$70,000 6-more than \$100,000 7-Declined to answer



0047B (ENR)

Web Version: 1.0; 1.02; 11-28-11

Date of assessment: (R3ASMDT)			(mm/dd/yyyy) Click here to view calendar
Screening ID:(R3SCRID)		(xx	xxx)
Bolded items require information from participant.			
Inclusion Criteria In order to meet eligibility ALL Inclusion answers must be "Yes".			
1. Registration as patient in the ED during study screening hours. (R3REGPAT)	🗌 No	C Ye	es 🗌 Unknown
2. Positive screen for problematic use of a non-alcohol, non-nicotine drug. (R3POSSCN)	🗌 No	Ye:	ies 🗌 Unknown
3. At least one day of problematic drug use (excluding alcohol or nicotine) in the past 30 days.(R3DRG30D) 🗌 No	🗌 Ye	ies 🗌 Unknown
4. Are you 18 years of age or older?(R3AGE)	□ No	Ye:	ies 🔲 Unknown
5. Adequate English Proficiency (based on RA interaction with participant):(R3ENGLSH)	_	_	ies 🗍 Unknown
6. Ability to provide informed consent (based on observation) (R3CONSNT)			ies 🗍 Unknown
7. Do you have access to a phone? (for booster sessions) (R3PHONE)			ies 🗌 Unknown
<u>Exclusion Criteria</u> In order to meet eligibility ALL Exclusion answers must be "No".			
1. Inability to participate due to emergency treatment (based on observation).(R3MEDTX)	No No	Ye:	ies 🗍 Unknown
2. Significant impairment of cognition or judgment rendering the person incapable of informed consent. (e.g., traumatic brain injury, delirium, intoxication)-(according to patient record and observation). (R3IMPAIR)	🗌 No	Ye:	ies 🗌 Unknown
3. Status as a prisoner or in police custody at the time of treatment. (based on observation). This also includes participants that are on probation, parole, house a rrest, and/or electronic monitoring (e.g. ankle bracelet). (R3PRISON)	🗌 No	Ye:	ies 🗌 Unknown
4. Are you currently engaged in an addiction treatment? (R3ADDTX)		Ye:	es 🗍 Unknown
This is defined according to participant self report for the past 30 days. Answer yes if participant e. a) Received therapy from a professional in which the primary goal was to treat an alcohol or non-rr Any 12-step/self-help groups (NA, AA, CA, Women for Sobriety, Moderation Management, Double b) Has taken medications as prescribed to treat an alcohol or non-nicotine drug addiction.	ither: icotine dr	rug a ddio	iction [INCLUDES: individual, group, inpatient, residential, and/or outpatient treatment, DOES NOT INCLUD
5. Do you live more than 50 miles from here? (R3LIVE50)	🗌 No	Ye:	ies 🗌 Unknown
6. Inability to provide sufficient contact information (all participants must provide at least 2 reliable locators) (R3NOCONT)			
7. Prior participation in the current study. (R3STUDY)	🗌 No	Ye:	es 🗌 Unknown
Eligibility for Randomization			
1. Is the participant eligible for the study?(R3ELGSTY)		Ye:	las
2. Is the participant eligible for randomization?(R3EL GRDM)		Ye:	

O-Declined study participation 1-Left E mergency D epartment 2-Medical complication 3-Death 4-J udgment of research staff 9-O ther


If "Judgment of research staff", please specify: (R3JUDGSP)

If "Other", please specify: (R3OTHRSP)


If "No", please specify:(R3RANOSP)

3. Audit-C Score:(*R3A UDITC*) 4. DAST-10 Score:(*R3DASTSR*)

Comments: (R3COMM)



□ <8 □ 8



NID	A Clinical Trials Network	
Hai	r Sample Form (HS2)	Web Version: 1.0; 1.00; 05-10-12
Segment (<i>PROTSEG</i>): Visit Number (<i>VISNO</i>):		
Date of assessment: (HSASMDT)	(mm/dd/yyyy) Click here to view calendar	
1. Hair sample collected: (HSCOLLTD) a. If "No", why was hair sample not collected: (HSNORESN)	No Yes 1-Refused 2-Insufficient hair 3-Phone interview 9-O ther	
If "Other", specify: (HS OTHSP)		
2. Date hair sample collected:(HSCOLLDT)	(mm/dd/yyyy) Click here to view calendar	
3. Initial hair sample collected from: (HSINITCF)		
4. Current hair sample collected from: (HSCOLFRM)	1-Head 2-Face 3-Arm 4-Underarm 5-C hest *Additional Options Listed Below	
If the current hair sample was collected from a part of the body other than the initial hair sample, explain why:(<i>HSDIFFCF</i>) 5. Hair sample ID:(<i>HSSAMPID</i>)		
Comments: (HSFCOMM)		

Additional Selection Options for HS2

Current hair sample collected from: 6-Leg

Intervention Record Form (IRF)

Web Version: 1.0; 1.01; 05-20-11

Segment (PROTSEG): Visit Number (VISNO): Date of assessment: (IRASMDT) (mm/dd/yyyy) Click here to view calendar 1. Was this session initiated?(IRSESINI) □ No □ Yes If session not initiated, select reason: (IRREASON) O-Refused 1-Left the Emergency Department 2-Deceased 3-Unavailable 4-0ther If "Other", specify: (IROTHRSP) 2. Time Start: (IRTMSTRT) (hh:mm) Time End: (IRTMEEND) (hh:mm) 3. Was this session interrupted?(IRINTRPD) O-No 1-Yes If "Yes", total length of interruption(s):(IRTIMEIP) (xxx) minutes 4. Were you able to complete the session?(IRSESCOM) O-No 1-Yes



5. Was the session recorded?(IRSESREC)

No Yes

If "Yes", upload the audio file using the link at the bottom of this form.

6. What was the total session time as indicated by the audio file (round up to whole minute)?(IRAUDIO)

(xx) (min)

Personal Rulers Worksheet

Importance Ruler:

0 Not at all important	1	2 Somewhat important	3	4 Fairly important	5	6 Important	7	8 Very important	9	10 Extre mely important
(IRIMPRUL)										

Confidence Ruler:

0 Not at all confide nt	1	2 Somewhat confident	3	4 Fairly confident	5	6 Confident	7	8 Very confident	9	10 Extremely confident
(IRCONRUL)										

Readiness Ruler:

0 Not at all ready	1	2 Somewhat ready	3	4 Fairly ready	5	6 Ready	7	8 Very ready	9	10 Completely ready
(IRREDRUL)										

Summary of session:(IRSESSUM)

Motivational Interviewing Treatment Integrity Code (MIT)

Interventionist type (MITTYPE):

Date of assessment: (MITASMDT)

(mm/dd/yyyy) Click here to view calendar

Web Version: 1.0; 1.01; 10-26-10

1. First sentence of audio recording: (MIFSTSNT)

2. Last sentence of audio recording:(MILSTSNT)

Global Ratings

	0					
	Classification	Low 1	2	3	4	High 5
1.	Evocation:	(MIEVOCAT)				
2.	Collaboration:	(MICOLLAB)				
3.	Autonomy/Support:	(MIAUTONO)				
4.	Direction:	(MIDIRECT)				
5.	Empathy:	(MIEMPTHY)				

Behavior Counts


Category	Sub ca teg ory	Totals
1. Giving information:	-	(MIGIVINF) (xxx)
2. MI:	Adherent (Asking permission, affirm, emphasize control, support)	(MIMIADH) (xxx)
3. MI:	Non-Adhe rent (Advise, confront, direct)	(MIMINADH) (xxx)
4. Question:	Closed	(MICLDQST) (xxx)
5. Question:	Open	(MIOPNQST) (XXX)
6. Reflections:	Simple	(MIRFTSIM) (xxx)
7. Reflections:	Complex	(MIRFTCPX) (xxx)
Total reflections:		(MIRFTTOT)

Rating/Scoring Chart

С	linician Behavior-Count	Interventionist	Be ginnin g	Competency

or Summary-Score	Ratings/Percents	Proficiency	
1. Global dinician rating:	(MIGCRT)	Average of 3.5	Average of 4
2. Spirit rating:	(MISPTRT)	Average of 3.5	Average of 4
3. Direction rating:	(MIDIRRT)	Average of 3.5	Average of 4
4. Empathy rating:	(MIEMPYRT)	Average of 3.5	Average of 4
5. Reflection to question ratio:	(MIRFQRO)	1	2
6. Percent open questions:	(MIOPNPC) %	50%	70%
7. Percent complex reflections:	(MICPXPC) %	40%	50%
8. Percent MI-Adherent:	(MIMIADPC) %	90%	100%

Comments: (MITCOMM)



Additional Selection Options for MIT

Interventionist type (*MITTYPE*) (key field): 1-Brief 2-Booster Visit 01 3-Booster Visit 02

Missed Visit (MV2)

Web Version: 1.0; 1.00; 04-29-11

Segment (PROTSEG): Visit Number (VISNO):

Missed visit target date:(MVTRGTDT)

Reason for missed visit: (MVREASON)

(mm/dd/yyyy) Click here to view calendar

Participant refused test
 Participant too ill
 Participant missed the study visit
 Unable to contact participant
 Information or sample not obtained
 A dditional Options Listed Below

If "Other", specify: (MVOTHRSP)

Additional Selection Options for MV2

Reason for missed visit: 6-Procedure or assessment not performed 9-Other

NIDA-Modified ASSIST V1.0 (NM2)

Segment (PROTSEG): Visit Number (VISNO):

Date of assessment: (NMASMDT)

(mm/dd/yyyy) Click here to view calendar

Web Version: 1.0; 1.01; 08-25-11

Introduction (Please read to participant)

The following questions relate to your experience with alcohol, cigarettes, and other drugs. Some of the substances we'll talk about are prescribed by a doctor (like pain medications). But I will only record those if you have taken them for reasons or in doses other than prescribed. I'll also ask you about illicit or illegal drug use.

Instructions: For each substance, mark in the appropriate column. For example, if the patient has ever used cocaine in their lifetime, put a mark in the "Yes" column in the "Cocaine" row.

Prescreen Question: In your lifetime which of the following substances have you ever used? For prescription medications, please report nonmedical use only.	No	Yes
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCLT)	
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCLT)	
c. Cannabis (marijuana, pot, grass, hash, etc.)	(NMCANLT)	
d. Cocaine (coke, crack, etc.)	(NMCOCNLT)	
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMLT)	
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHLT)	
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHLLT)	
h. Sed atives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDLT)	
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALLT)	
j. Street opioids (heroin, opium, etc.)	(NM OPDSLT)	
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NMRXOPLT)	
I. Other	(NMOTHRLT)	
If "Other", specify:(NM OTLTSP)		1

Question 1 of the NIDA-Modified ASSIST V1.0

1. In the past three months, how often have you used the substances you mentioned (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBC3M) 🗌				
b. Alcoholic beverages (beer, wine, liquor, etc.	(NMALC3M) 🗌				
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCAN3M)				
d. Cocaine (coke, crack, etc.)	(NMCOCN3M)				

e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIM3M)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NM МЕТНЗМ)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHL3M)		
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSED3M)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHAL3M)		
j. Street opioids (heroin, opium, etc.)	(NM OPDS3M)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NM RХОРЗМ)		
I. Other specify: (NM OT3MSP)	(NM ОТНРЗМ) 🗌		

Question 2-7 of the NIDA-Modified ASSIST V1.0

2. In the past 3 months, how often have you had a strong desire or urge to use (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCDR)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCDR)				
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANDR)				
d. Cocaine (coke, crack, etc.)	(NMCOCNDR)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMDR)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHDR)				
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHLDR)				
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDDR)				
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALDR)				
j. Street opioids (heroin, opium, etc.)	(NM OPDSDR)				
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, bupren orphine, etc.)	(NMRXOPDR)				
I. Other specify: (NM OTDRSP)	(NMOTHRDR)				

3. During the past 3 months, how often has your use of (first drug, second drug, etc) led to health, social, legal or financial problems?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCPR)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCPR)				
c. Cannabis (marijuana, pot, grass, hash, etc.)	(NMCANPR)				
d. Cocaine (coke, crack, etc.)	(NMCOCNPR)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMPR)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHPR)				
g. Inhalants (ni trous oxide, glue, gas, paint thinner, etc.)	(NMINHPR)				

h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NM SEDPR)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALPR)		
j. Street opioids (heroin, opium, etc.)	(NMOPDSPR)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NMRXOPPR)		
I. Other specify: (NM OTPRSP)	(NMOTHRPR)		

4. In the past 3 months, how often have you failed to do what was normally expected of you because of your use of (first drug, second drug, etc)?	Never	Onceor twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCFL)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCFL)				
c. Cannabis (marijuana, pot, grass, hash, etc.)	(NMCANFL)				
d. Cocaine (coke, crack, etc.)	(NMCOCNFL)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMFL)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHFL)				
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHFL)				
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDFL)				
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALFL)				
j. Street opioids (heroin, opium, etc.)	(NM OPDSFL)				
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NM RXOPFL)				
I. Other specify:(NM OTFLSP)	(NM OTHRFL)				

5. Has a friend or relative or anyone else ever expressed concern about your use of (first drug, second drug, etc)?	No,never	Yes, but not in the past 3 months	Yes, in the past 3 months
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCCR)		
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCCR)		
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANCR)		
d. Cocaine (coke, crack, etc.)	(NMCOCNCR)		
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMCR)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHCR)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHCR)		
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NM SEDCR)		

i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALCR)	
j. Street opioids (heroin, opium, etc.)	(NMOPDSCR)	
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, bupren orphine, etc.)	(NMRXOPCR)	
I. Other specify: (NM CR0 TSP)	(NMOTHRCR)	

6. Have you ever tried and failed to control, cut down, or stop using (first drug, second drug, etc)?	No, never	Yes, but not in the past 3 months	Yes, in the past 3 months
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCCL)		
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCCL)		
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANCL)		
d. Cocaine (coke, crack, etc.)			
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMCL)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHCL)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHCL)		
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDCL)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALCL)		
j. Street opioids (heroin, opium, etc.)	(NM OPDSCL)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NMRXOPCL)		
I. Other specify: (NM OTCLSP)	(NMOTHRCL)		

7. Have you ever used any drug by injection (NONMEDICAL USE ONLY)?	No, never	Yes, but not in the past 3 months	Yes, in the past3 months
	(NMINJECT)		

NIDA-Modified ASSIST V1.0 (NMA)

Segment (PROTSEG): Visit Number (VISNO):

Date of assessment: (NMASMDT)

(mm/dd/yyyy) Click here to view calendar

Web Version: 1.0; 1.00; 08-18-10

Introduction (Please read to participant)

The following questions relate to your experience with alcohol, cigarettes, and other drugs. Some of the substances we'll talk about are prescribed by a doctor (like pain medications). But I will only record those if you have taken them for reasons or in doses other than prescribed. I'll also ask you about illicit or illegal drug use.

Instructions: For each substance, mark in the appropriate column. For example, if the patient has ever used cocaine in their lifetime, put a mark in the "Yes" column in the "Cocaine" row.

Prescreen Question: In your lifetime which of the following substances have you ever used? For prescription medications, please report nonmedical use only.	No	Yes
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCLT)	
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCLT)	
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANLT)	
d. Cocaine (coke, crack, etc.)	(NMCOCNLT)	
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NM STIMLT)	
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHLT)	
g. Inhalants (ni trous oxide, glue, gas, paint thinner, etc.)	(NMINHLLT)	
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDLT)	
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALLT)	
j. Street opioids (heroin, opium, etc.)	(NM OPDSLT)	
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NM RX OPLT)	
I. Other	(NM OTHRLT)	
If "Other", specify:(NM OTLTSP)		

Question 1 of the NIDA-Modified ASSIST V1.0

1. In the past three months, how often have you used the substances you mentioned (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBC3M)				
b. Alcoholic beverages (beer, wine, liquor, etc.	(NMALC3M)				
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCAN3M)				
d. Cocaine (coke, crack, etc.)	(NMCOCN3M)				

e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIM3M)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NM МЕТНЗМ)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHL3M)		
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSED3M)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHAL3M)		
j. Street opioids (heroin, opium, etc.)	(NM OPDS3M)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NM RХОРЗМ)		
I. Other specify: (NM OT3MSP)	(NM ОТНРЗМ) 🗌		

Question 2-7 of the NIDA-Modified ASSIST V1.0

2. In the past 3 months, how often have you had a strong desire or urge to use (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCDR)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCDR)				
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANDR)				
d. Cocaine (coke, crack, etc.)	(NMCOCNDR)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMDR)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHDR)				
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHLDR)				
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDDR)				
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALDR)				
j. Street opioids (heroin, opium, etc.)	(NM OPDSDR)				
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, bupren orphine, etc.)	(NMRXOPDR)				
I. Other specify: (NM OTDRSP)	(NMOTHRDR)				

3. During the past 3 months, how often has your use of (first drug, second drug, etc) led to health, social, legal or financial problems?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCPR)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCPR)				
c. Cannabis (marijuana, pot, grass, hash, etc.)	(NMCANPR)				
d. Cocaine (coke, crack, etc.)	(NMCOCNPR)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMPR)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHPR)				
g. Inhalants (ni trous oxide, glue, gas, paint thinner, etc.)	(NMINHPR)				

h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NM SEDPR)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALPR)		
j. Street opioids (heroin, opium, etc.)	(NMOPDSPR)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NMRXOPPR)		
I. Other specify:(NM OTPRSP)	(NMOTHRPR)		

4. In the past 3 months, how often have you failed to do what was normally expected of you because of your use of (first drug, second drug, etc)?	Never	Once or Twice	Monthly	Weekly	Daily or Almost Daily
a. Tobac∞ products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCFL)				
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCFL)				
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANFL)				
d. Cocaine (coke, crack, etc.)	(NMCOCNFL)				
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMFL)				
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMM ETHFL)				
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NM INHFL)				
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDFL)				
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALFL)				
j. Street opioids (heroin, opium, etc.)	(NM OPDSFL)				
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.)	(NM RX OPFL)				
I. Other specify: (NM OTFLSP)	(NM OTHRFL)				

5. Has a friend or relative or anyone else ever expressed concern about your use of (first drug, second drug, etc)?	No, never	Yes, but not in the past 3 months	Yes, in the past 3 months
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCCR)		
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCCR)		
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NM CANCR)		
d. Cocaine (coke, crack, etc.)	(NMCOCNCR)		
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMCR)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHCR)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHCR)		

h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NM SEDCR)	
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALCR)	
j. Street opioids (heroin, opium, etc.)	(NMOPDSCR)	
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, bupren orphine, etc.)	(NMRXOPCR)	
I. Other specify: (NM CRO TSP)	(NMOTHRCR)	


6. Have you ever tried and failed to control, cut down, or stop using (first drug, second drug, etc)?	No, never	Yes, but not in the past 3 months	Yes, in the past 3 months
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.)	(NMTOBCCL)		
b. Alcoholic beverages (beer, wine, liquor, etc.)	(NMALCCL)		
c. Can nabis (marijuana, pot, grass, hash, etc.)	(NMCANCL)		
d. Cocaine (coke, crack, etc.)	(NMCOCNCL)		
e. Prescribed Amphetamine type stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.)	(NMSTIMCL)		
f. Methamphetamine (speed, crystal meth, ice, etc.)	(NMMETHCL)		
g. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)	(NMINHCL)		
h. Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.)	(NMSEDCL)		
i. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.)	(NMHALCL)		
j. Street opioids (heroin, opium, etc.)	(NM OPDSCL)		
k. Prescribed opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, bupren orphine, etc.)	(NM RX OPCL)		
I. Other specify: (NM OTCLSP)	(NMOTHRCL)		

7. Have you ever used any drug by injection (NONMEDICAL USE ONLY)?	No, never	Yes, but not in the past 3 months	Yes, in the past3 months
	(NMINJECT)		

Non-stu	dy Treatment Form (NTF)	
Segment (<i>PROTSEG</i>): Visit Number (<i>VISNO</i>):		Web Version: 1.0; 1.00; 01-03-11
Date of baseline assessment:(<i>NTBASMDT</i>) Date of assessment:(<i>NTASMDT</i>)	(mm/dd/yyyy) (mm/dd/yyyy) Click here to view calendar	
 Did the participant leave the Emergency Department without being seen for their medical issue? (NTPTSEEN) 	□ No □ Yes	
2. Was the participant hospitalized?(NTHO SPTL)	No Yes	
a. If Yes, (NTHOSSDT)	(mm/dd/yyyy) through (NTHOSEDT) (mm/dd/yyyy)	
3. Did the participant receive other substance related interventions during the Emergency Department visit?(NTINTERV)	□ No □ Yes	
4. Did the participant receive a substance use referral from the Emergency Department (not research)? (NTRE FRL)	No Yes	
5. Was the participant discharged with medications for substance use (e.g., with drawal meds)? (NTDISCRG)	No Yes	
6. Length of time in the Emergency Department:(NTTIMEER)	(xx) hours	
7. Emergency Department discharge diagnosis: (Provide the top 4 diagnoses)(NT1DIAG)		
(NT2DIAG)		

(NT3DIAG)

(NT4DIAG)



Comments: (NTFCOMM)

Protocol Violation Log (PV2)

Web Version: 1.0; 1.02; 12-15-10

Date of Violation (PVDATE): Protocol Violation Number (PVSEQNUM):

To be filled in by person(s) reporting this protocol violation:

1. Violation type:(PVTYPE47)

Z01-INFORMEDCONSENT PROCEDURES

01A - No consent/assentobtained

01C - Invalid/incomplete informed consent

01D- Unauthorized assessments and /or procedures conducted prior to obtaining informed consent

01E - HIPAA release not obtained

*Additional Options Listed Below

If "Other" is indicated, please provide the specification: (PVTPSP47)

2. Description of violation: (PVDESC)



3. Has this protocol violation been resolved?(PVRESOL)





4. Does this protocol violation require IRB reporting?(PVIRB)

□ No □ Yes

If "Yes", provide date reported:(PVIRBDT)

Comments: (PVLCOMM)

(mm/dd/yyyy)



Additional Selection Options for PV2

Protocol Violation Number (PVSEQNUM) (key field):

01-1st Protocol Violation of the day 02-2nd Protocol Violation of the day 03-3rd Protocol Violation of the day 04-4th Protocol Violation of the day 05-5th Protocol Violation of the day 06-6th Protocol Violation of the day 07-7th Protocol Violation of the day 08-8th Protocol Violation of the day 09-9th Protocol Violation of the day 10-10th Protocol Violation of the day

Violation type:

01Z- Other (specify) 02-INCLUSION/EXCLUSION CRITERIA Z04-LABORATORY ASSESSMENT S/PROCEDURES 04B- Testing completed outside window 04C- Testing not completed as per protocol 04D- Unauthorized test/procedure obtained 04Z- Other (specify) Z05-STUDY PROCEDURES/ASSESSMENTS 05A- Protocol required procedures not obtained 05B- Procedures/Assessments not completed as per protocol 05C- Procedures/Assessments obtained outside the visit timeframes 05Z- Other (specify) Z06-ADVERSE EVENT 06A- SAE not reported 06B- SAE reported out of time window 06Z- Other (specify) **Z07-RANDOMIZATION PROCEDURES** 07A- Randomization procedures not followed (e.g., outside window, out of sequence, etc.) 07B- Ineligible participant randomized 07 E- Incorrect treatment assignment 07Z- Other (specify) **Z09-BEHAVIORAL INTERVENTION** 09A- Intervention not provided per protocol schedule or visit window timeframe 09B- Incorrect intervention assignment 09C- Referral not performed per protocol 09Z- Other (specify) Z10-VISIT SCHEDULE/INTERVAL 10A- Visit conducted outside of window 10Z- Other (specify) **Z99-OTHER SIGNIFICANT VIOLATIONS** 99A- Destroying study materials prior to authorization from Lead Node

- 99B- Site starting the study prior to obtaining appropriate IRB(s) and/or CTM approvals
- 99C- Using advertising materials or brochures without prior IRB approval

99Z- Other (specify)

Protocol Violation Log (PVL)

Web Version: 1.0; 3.04; 10-04-12

Date of Violation (PVDATE): Protocol Violation Number (PVSEQNUM):

To be filled in by person(s) reporting this protocol violation:

1. Violation type:(PVTYPE47)

Z01-INFORMED CONSENT PROCEDURES

01A-Noconsent/assentobtained

01C - Invalid/incomplete informed consent

01D- Unauthorized assessments and /or procedures conducted prior to obtaining informed consent

01E- HIPAA release not obtained *A dditional Options Listed Below

If "Other" is indicated, provide the specification: (PVTPSP47)

2. Description of violation: (PVDESC)



3. Has this protocol violation been resolved?(PVRESOL)





4. Does this protocol violation require IRB reporting?(PVIRB)

□ No □ Yes

If "Yes", provide date reported:(PVIRBDT)

Comments: (PVLCOMM)

(mm/dd/yyyy) Click here for calendar

Additional Selection Options for PVL

Protocol Violation Number (PVSEQNUM) (key field):

01-1st Protocol Violation of the day 02-2nd Protocol Violation of the day 03-3rd Protocol Violation of the day 04-4th Protocol Violation of the day 05-5th Protocol Violation of the day 06-6th Protocol Violation of the day 07-7th Protocol Violation of the day 08-8th Protocol Violation of the day 09-9th Protocol Violation of the day 10-10th Protocol Violation of the day

Violation type:


01Z- Other (specify) 02-INCLUSION/EXCLUSION CRITERIA Z04-LABORATORY ASSESSMENT S/PROCEDURES 04B- Testing completed outside window 04C- Testing not completed as per protocol 04D- Unauthorized test/procedure obtained 04Z- Other (specify) Z05-STUDY PROCEDURES/ASSESSMENTS 05A- Protocol required procedures not obtained 05B- Procedures/Assessments not completed as per protocol 05C- Procedures/Assessments obtained outside the visit timeframes 05Z- Other (specify) Z06-ADVERSE EVENT 06A- SAE not reported 06B- SAE reported out of time window 06Z- Other (specify) **Z07-RANDOMIZATION PROCEDURES** 07A- Randomization procedures not followed (e.g., outside window, out of sequence, etc.) 07B- Ineligible participant randomized 07E- Incorrect treatment assignment 07Z- Other (specify) **Z09-BEHAVIORAL INTERVENTION** 09A- Intervention not provided per protocol schedule or visit window timeframe 09B- Incorrect intervention assignment 09C- Referral not performed per protocol 09Z- Other (specify) Z10-VISIT SCHEDULE/INTERVAL 10A- Visit conducted outside of window 10Z- Other (specify) **Z99-OTHER SIGNIFICANT VIOLATIONS** 99A- Destroying study materials prior to authorization from Lead Node

- 99B- Site starting the study prior to obtaining appropriate IRB(s) and/or CTM approvals
- 99C- Using advertising materials or brochures without prior IRB approval

99Z- Other (specify)

NIDA Clinical Trials Network				
	Referral Form (RLF)			
Segment (<i>PROTSEG</i>): Visit Number (<i>VISNO</i>):		Web Version: 1.0; 1.01; 09-17-10		
Date of assessment (RLASMDT)	(mm/dd/yyyy) Click here to view calendar			
1. Was the baseline NIDA Modified Assist completed?(RLNMACMP)	V No Yes			
2. Were TLFBs completed for the 30 days prior to screening?(<i>RLTFBCMP</i>) If "No", run the "Missing TLFB Forms Report" to determine which TLFB forms still need to	□ No Ves be completed.			
3. Treatment Assignment: (RLTREAT)	SAR BI-B			
4. NM-ASSIST Score:(RLASSIST)	NM-ASSIST Score <27 NM-ASSIST Score 27			
No referral required Referral required Initiate brief intervention with interventionist				
5. Was participant referred for treatment?(<i>RLREFER</i>) If "Referred" and NM-ASSIST score is <27, explain:(<i>RLREFSP</i>)	No Yes			
Comments: (RLFCOMM)				

NIDA	A Clinical Trials Network	
Stue	dy Termination (ST2)	Web Version: 1.0; 1.00; 10-05-10
1. Date of study completion or last attended study visit: (TRTRMDT)	(mm/dd/yyyy)	
2. Did the participant complete the study?(TRCOMPLT)	No Yes	
If "No", please select the primary reason for study termination:(<i>TRTRMRES</i>)	01-Participant incarcerated for duration of study 02-Participant terminated for clinical reasons 03-Participant terminated due to AE /S AE 04-Participant withdrew consent 05-Participant died *A dditional Options Listed Below	
If "Participant terminated for other reason", provide other reason:(<i>TRTRMOSP</i>)		
Provide further information concerning above termination reason (if not "Participant terminated for other reason"): (<i>TRTMRSSP</i>)		



Investigator's Signature

I have reviewed all the data recorded on all CRF pages and certify that they are accurate and complete to the best of my knowledge.

Principal Investigator or designee: (TRPISIGN)

Date:(TRPISGDT)

(mm/dd/yyyy)

Additional Selection Options for ST2

If "No", please select the primary reason for study termination: 06-Participant terminated due to protocol violation 99-Participant terminated for other reason

	NIDA Clinical Trials Network	
	Study Termination (STT)	Web Version: 1.0; 3.00; 05-10-12
1. Date of study completion or last attended study visit (TRTRMDT)	(mm/dd/yyyy) Click here for calendar	
2. Did the participant complete the study?(TRCOMPLT)	No Yes	
If "No", select the primary reason for study termination: (<i>TRTRMRES</i>)	01-Participant incarcerated for duration of study 02-Participant terminated for clinical reasons 03-Participant terminated due to AE /S AE 04-Participant withdrew consent 05-Participant died *A dditional Options Listed Below	
If "Participant terminated for other reason", provide other reason:(<i>TRTRMOSP</i>)		
3. Comments: (STTCOMM)		

Investigator's Signature

I have reviewed all the data recorded on all CRF pages and certify that they are accurate and complete to the best of my knowledge.

Principal Investigator or designee: (TRPISIGN)

Date:(TRPISGDT)

Additional Selection Options for STT

If "No", select the primary reason for study termination: 06-Participant terminated due to protocol violation 99-Participant terminated for other reason

Time Line Follow Back (T47) Web Version: 1.0; 1.01; 10-04-12 Segment (PROTSEG): TLFB Date (TFASMTDT): 🗆 No 🗌 Yes 1. Have any illicit substances or alcohol been taken on this day?(TFSUBALC) 🗆 No 🗌 Yes 2. Alcoholic beverages: (TFALCOHL) a. Number of standard drinks: (TFNMDRNK) (x x) 3. Cannabis: (TFCANNAB) 🗆 No 🗌 Yes a. Route: (TFCANROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used: (TFCANUSE) 1-Single use 2-Several uses 3-Steady or Heavy use c. Street value of amount used (enter dollar amount, no decimals):(TFCANVAL) \$ (XXX) 4. Cocaine: (TFCOCAIN) 🗆 No 🗌 Yes a. Route: (TFCOCROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used: (TFCOCUSE) 1-Single use 2-Several uses 3-Steady or Heavy use c. Street value of amount used (enter dollar amount, no decimals):(TFCOCVAL) \$ (xxxx) 5. Prescribed Amphetamines type stimulants:(TFPRAMPH) □ No □ Yes

b. Amount used: (TFPAMUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFPAM VAL)

6. Methamphetamine: (TFMETAMP)

a.Route:(TFMETROU)

b. Amount used: (TFMETUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFMETVAL)

7. Inhalants: (TFINHALE)

a. Route: (TFINHROU)

b. Amount used: (TFINHUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFINHVAL)

8. Sedatives or sleeping pills:(*TFSEDSLP*) a. Route:(*TFSSPROU*)

b. Amount Used(TFSSPUSE)

4-04-N 5-05-1		ed Below
2-Sev	jle use eral uses ady or Heavy use	
\$	(xxx)	
🗌 No	Yes	
4-04-N 5-05-1		ed Below
2-Sev	gleuse eraluses adyorHeavyuse	
\$	(xxx)	
□ No	Yes	
4-04-N 5-05-1		ed Below

1-Single use 2-Several uses 3-S teady or Heavy use

(xxx)

\$

No Yes

1-01-Oral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional O ptions Listed Below

2-Several uses 3-Steady or Heavy use c. Street value of amount used (enter dollar amount, no decimals):(TFSSP VAL)

9. Hallucinogens: (TFHALLCN) No Yes a. Route: (TFHALROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used: (TFHALUSE) 1-Single use 2-Several uses 3-S teady or Heavy use c. Street value of amount used (enter dollar amount, no decimals):(TFHALVAL) \$ (xxx) 10. Street opioids: (TFSTOPIO) No Yes a. Route:(TFSOPROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used:(TFSOPUSE) 1-Single use 2-Several uses 3-S teady or Heavy use c. Street value of amount used (enter dollar amount, no decimals)(TFSOPVAL) \$ (XXX) 11. Prescribed opioids:(TFPROPIO) No Yes a. Route:(TFPOPROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used:(TFPOPUSE) 1-Single use 2-Several uses 3-S teady or Heavy use c. Street value of amount used (enter dollar amount, no decimals)(TFPOPVAL) \$ (XXX) 12. Other drugs: (TFO THDRG) 🗌 No 🗌 Yes a. Number of other drugs (up to 9): (TFNMOTH) (x) Other Drug 1 b. Specify Other Drug 1:(TFOTH1SP)

(XXX)

\$

d. Amount used: (TFOT1USE)

e. Street value of amount used (enter dollar amount, no decimals):(TFOT1VAL)

Other Drug 2 f. Specify Other Drug 2:(TFOTH2SP)

g. Route Other Drug 2: (TFOTH2RT)

h. Amount used: (TFOT2USE)

i. Street value of amount used (enter dollar amount, no decimals):(TFOT2VAL)

Other Drug 3

j. Specify Other Drug 3:(TFOTH3SP)

k. Route Other Drug 3: (TFOTH3RT)

I. Amount used: (TFOT3USE)


m. Street value of amount used (enter dollar amount, no decimals):(TFOT3VAL)

Other Drug 4

n. Specify Other Drug 4:(TFOTH4SP)

o. Route Other Drug 4:(TFOTH4RT)

5-05-IV I	sal oking n-IV Injection
1-Single 2-Severa 3-Steady	
\$	(xxx)
5-05-IV I	sal oking 1-IV Injection
1-Single 2-Severa 3-Steady	
\$	(xxx)
5-05-IV I	sal oking n-IV Injection
1-Single 2-Severa 3-Steady	
\$	(xxx)
1-01-Ora 2-02-Nas 3-03-Sm 4-04-Nor 5-05-IV II	sal oking n-IV Injection



af. Amount used: (TFOT8USE)

ag. Street value of amount used (enter dollar amount, no decimals):(TFOT8VAL)


Other Drug 9 ah. Specify Other Drug 9:(TFOTH9SP)

ai. Route Other Drug 9: (TFOTH9RT)

aj. Amount used: (TFOT9USE)

ak. Street value of amount used (enter dollar amount, no decimals):(TFOT9VAL)

Comments:(TFBCOMM)



Additional Selection Options for T47

Route: 99-99-Other

Route: 6-06-Inhale 99-99-Other

NIDA Clinical Trials Network

TLFB Assessment Period (TA2)

Web Version: 1.0; 1.00; 02-27-12

Segment (PROTSEG): Visit Number (VISNO):

1. Date of assessment: (TAASMTDT)

2. Assessment period:(TATFSTDT)

3. Assessment period:(TATFSTDT)

4. Assessment period:(TATFSTDT)

5. Assessment period:(TATFSTDT)

6. Assessment period:(TATFSTDT)

(TATFENDT)

7. Was this assessment period reconstructed due to a missed visit? (TARECON)

8. Have any illicit substances or alcohol been taken during this assessment period?(TASUBALC)

(mm/dd/yyyy) Click here to view calendar				
From:	(mm/dd/yyyy) Click here to view calendar			
From:	(mm/dd/yyyy) Click here to view calendar			
From:	(mm/dd/yyyy) Click here to view calendar			
From:	(mm/dd/yyyy) Click here to view calendar			
From:	(mm/dd/yyyy) Click here to view calendar			
T o:	(mm/dd/yyyy) Click here to view calendar			
No Yes				
No Yes				

NIDA Clinical Trials Network

TLFB Assessment Period (TAP)

Web Version: 1.0; 1.04; 08-20-12

Segment (PROTSEG): Visit Number (VISNO):

1. Date of assessment: (TAASMTDT)

2. Assessment period:(TATFSTDT)


3. Assessment period:(TATFSTDT)

(TATFENDT)

4. Was this assessment period reconstructed due to a missed visit?(TARECON)

5. Have any illicit substances or alcohol been taken during this assessment period?(TASUBALC)

(mm/dd/yyyy) Click here to view calendar				
From:	(mm/dd/yyyy) Click here to view calendar			
From:	(mm/dd/yyyy) Click here to view calendar			
То:	(mm/dd/yyyy) Click here to view calendar			
	es			
	es			



b. Amount used: (TFPAMUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFPAMVAL)

6. Methamphetamine: (TFMETAMP)

a.Route:(TFMETROU)

b. Amount used: (TFMETUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFMETVAL)

7. Inhalants: (TFINHALE)

a. Route: (TFINHROU)

b. Amount used: (TFINHUSE)

c. Street value of amount used (enter dollar amount, no decimals):(TFINHVAL)


8. Sedatives or sleeping pills: (TFSEDSLP) a. Route: (TFSSPROU)

b. Amount Used(TFSSPUSE)

1-01-Oral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional O ptions Listed Below
1-Single use 2-Several uses 3-Steady or Heavy use
\$ (xxxx)
No Yes
1-01-Oral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below
1-Single use 2-Several uses 3-Steady or Heavy use
\$ (XXXX)
No Yes
1-01-Oral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below

1-Single use 2-Several uses 3-S teady or Heavy use \$

(xxxx)



c. Street value of amount used (enter dollar amount, no decimals):(TFSSPVAL)

9. Hallucinogens: (TFHALLCN) No Yes a. Route: (TFHALROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used: (TFHALUSE) 1-Single use 2-Several uses 3-S teady or Heavy use c. Street value of amount used (enter dollar amount, no decimals):(TFHALVAL) \$ (xxxx) 10. Street opioids: (TFSTOPIO) No Yes a. Route:(TFSOPROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used:(TFSOPUSE) 1-Single use 2-Several uses 3-S teady or Heavy use c. Street value of amount used (enter dollar amount, no decimals)(TFSOPVAL) \$ (XXXX) 11. Prescribed opioids:(TFPROPIO) No Yes a. Route:(TFPOPROU) 1-01-0ral 2-02-Nasal 3-03-S moking 4-04-Non-IV Injection 5-05-IV Injection *Additional Options Listed Below b. Amount used:(TFPOPUSE) 1-Single use 2-Several uses 3-Steady or Heavy use c. Street value of amount used (enter dollar amount, no decimals)(TFPOPVAL) \$ (xxxx) 12. Other drugs: (TFO THDRG) 🗌 No 🗌 Yes a. Number of other drugs (up to 9): (TFNMOTH) (x) Other Drug 1 b. Specify Other Drug 1:(TFOTH1SP)

\$

(XXXX)

d. Amount used: (TFOT1USE)

e. Street value of amount used (enter dollar amount, no decimals):(TFOT1VAL)

Other Drug 2 f. Specify Other Drug 2:(TFOTH2SP)

g. Route Other Drug 2: (TFOTH2RT)

h. Amount used: (TFOT2USE)

i. Street value of amount used (enter dollar amount, no decimals):(TFOT2VAL)

Other Drug 3

j. Specify Other Drug 3:(TFOTH3SP)

k. Route Other Drug 3: (TFOTH3RT)


I. Amount used: (TFOT3USE)


m. Street value of amount used (enter dollar amount, no decimals):(TFOT3VAL)


Other Drug 4

n. Specify Other Drug 4:(TFOTH4SP)

o. Route Other Drug 4: (TFOTH4RT)







af. Amount used: (TFOT8USE)

ag. Street value of amount used (enter dollar amount, no decimals):(TFOT8VAL)


Other Drug 9 ah. Specify Other Drug 9:(TFOTH9SP)

ai. Route Other Drug 9: (TFOTH9RT)

aj. Amount used: (TFOT9USE)

ak. Street value of amount used (enter dollar amount, no decimals):(TFOT9VAL)

Comments:(TFBCOMM)



Additional Selection Options for TF2

Route: 99-99-Other

Route: 6-06-Inhale 99-99-Other

Participant Tracking Log (TRK)

Web Version: 1.0; 2.00; 02-01-12

Segment (PROTSEG): Visit Number (VISNO):

	Date	Time (in minutes)	Staff ID
1. (TR01DT)	(mm/dd/yyyy) Calendar	(TR01TM) (xxx)	(TR01ID) (XXXXX)
2. (TR02DT)	(mm/dd/yyyy) Calendar	(TR02TM) (xxx)	(TR02ID) (xxxxx)
3. (TR03DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR03TM) (xxx)	(TR03ID) (xxxxx)
4. (TR04DT)	(mm/dd/yyyy) Calendar	(TR04TM) (xxx)	(TR04ID) (xxxxx)
5. (TR05DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR05TM) (xxx)	(TR05ID) (XXXXX)
6. (TR06DT)	(mm/dd/yyyy) Calendar	(TR06TM) (xxx)	(TR06ID) (xxxxx)
7. (TR07DT)	(mm/dd/yyyy) Calendar	(TR07TM) (xxx)	(TR07ID) (xxxxx)
8. (TR08DT)	(mm/dd/yyyy) Calendar	(TR08TM) (xxx)	(TR08ID) (xxxxx)
9. (TR09DT)	(mm/dd/yyyy) Calendar	(TR09TM) (xxx)	(TR09ID) (XXXXX)
10. (TR10DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR10TM) (xxx)	(TR10ID) (XXXXX)

Date		Time (in minutes)		Staff ID
11. (TR11DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR11TM) (xx	x) (TR11ID)	(xxxxx)
12. (TR12DT)	(mm/dd/yyyy) Calendar	(TR12TM) (xx	x) (TR12ID)	(xxxxx)
13. (TR13DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR13TM) (xx	x) (TR13ID)	(xxxxx)
14. (TR14DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR14TM) (xx	x) (TR14ID)	(xxxxx)
15. (TR15DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR15TM) (xx	x) (TR15ID)	(xxxxx)
16. (TR16DT)	(mm/dd/yyyy) Calendar	(TR16TM) (xx	x) (TR16ID)	(xxxxx)
17. (TR17DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR17TM) (xx	x) (TR17ID)	(xxxxx)
18. (TR18DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR18TM) (xx	x) (TR18ID)	(xxxxx)
19. <i>(TR19DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(TR19TM) (xx	x) (TR19ID)	(xxxxx)
20. (TR20DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR20TM) (xx	x) (TR20ID)	(xxxxx)

C	Date	Time (in minutes)	Staff ID
21. (TR21DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR21TM) (xxx)	(TR21ID) (XXXXX)
22. (TR22DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR22TM) (xxx)	(TR22ID) (XXXXX)
23. (TR23DT)	(mm/dd/yyyy) Calendar	(TR23TM) (xxx)	(TR23ID) (xxxxx)
24. (TR24DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR24TM) (xxx)	(TR24ID) (xxxxx)
25. (TR25DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR25TM) (xxx)	(TR25ID) (XXXXX)
26. (TR26DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR26TM) (xxx)	(TR26ID) (XXXXX)
27. (TR27DT)	(mm/dd/yyyy) Calendar	(TR27TM) (xxx)	(TR27ID) (xxxxx)
28. (TR28DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR28TM) (xxx)	(TR28ID) (xxxxx)
29. (TR29DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR29TM) (xxx)	(TR29ID) (xxxxx)
30. (TR30DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR30TM) (xxx)	(TR30ID) (xxxxx)

	Date	Time (in minutes)	Staff ID
31. <i>(TR31DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(TR31TM) (xxx)	(TR31ID) (XXXXX)
32. (TR32DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR32TM) (xxx)	(TR32ID) (XXXXX)
33. (TR33DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR33TM) (xxx)	(TR33ID) (xxxxx)
34. (TR34DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR34TM) (xxx)	(TR34ID) (xxxxx)
35. (TR35DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR35TM) (xxx)	(TR35ID) (xxxxx)
36. (TR36DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR36TM) (xxx)	(TR36ID) (xxxxx)
37. (TR37DT)	(mm/dd/yyyy) Calendar	(TR37TM) (xxx)	(TR37ID) (xxxxx)
38. (TR38DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR38TM) (xxx)	(TR38ID) (xxxxx)
39. <i>(TR39DT)</i>	(mm/dd/yyyy) <u>Calendar</u>	(TR39TM) (xxx)	(TR39ID) (xxxxx)
40. (TR40DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR40TM) (xxx)	(TR40ID) (xxxxx)

Date	Time (in minutes)	Staff ID
41. (TR41DT) (mm/dd/yyyy) <u>Calendar</u>	(TR41TM) (xxx)	(TR411D) (xxxxx)
42. (TR42DT) (mm/dd/yyyy) <u>Calendar</u>	(TR42TM) (xxx)	(TR42ID) (xxxxx)
43. (TR43DT) (mm/dd/yyyy) <u>Calendar</u>	(TR43TM) (xxx)	(TR43ID) (xxxxx)

44. (TR44DT) (mm/dd/yyyy) <u>Calendar</u>	(TR44TM) (xxx)	(TR44ID) (xxxxx)
45. (TR45DT) (mm/dd/yyyy) Calendar	(TR45TM) (xxx)	(TR45ID) (xxxxx)
46. (TR46DT) (mm/dd/yyyy) Calendar	(TR46TM) (xxx)	(TR46ID) (xxxxx)
47. (TR47DT) (mm/dd/yyyy) <u>Calendar</u>	(TR47TM) (xxx)	(TR47ID) (xxxxx)
48. (TR48DT) (mm/dd/yyyy) Calendar	(TR48TM) (xxx)	(TR48ID) (xxxxx)
49. (TR49DT) (mm/dd/yyyy) <u>Calendar</u>	(TR49TM) (xxx)	(TR49ID) (xxxxx)
50. (TR50DT) (mm/dd/yyyy) <u>Calendar</u>	(TR50TM) (xxx)	(TR50ID) (xxxxx)

Date		Time (in minutes)	Staff ID
51. (TR51DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR51TM) (xx	xx) (TR511D) (xxxxx)
52. (TR52DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR52TM) (xx	xx) (TR52ID) (xxxxx)
53. (TR53DT)	(mm/dd/yyyy) Calendar	(TR53TM) (xx	xx) (TR53ID) (xxxxx)
54. (TR54DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR54TM) (xx	xx) (TR54ID) (xxxxx)
55. (TR55DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR55TM) (xx	xx) (TR55ID) (xxxxx)
56. (TR56DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR56TM) (xx	(TR56ID) (XXXXX)
57. (TR57DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR57TM) (xx	xx) (TR57ID) (xxxxx)
58. (TR58DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR58TM) (xx	xx) (TR58ID) (xxxxx)
59. (TR59DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR59TM) (xx	xx) (TR59ID) (xxxxx)
60. (TR60DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR60TM) (xx	xx) (TR60ID) (xxxxx)

Date	Time (in minutes)	Staff ID
61. (TR61DT) (mm/dd/yyyy) Calendar	(TR61TM) (xxx)	(TR61ID) (xxxxx)
62. (TR62DT) (mm/dd/yyyy) Calendar	(TR62TM) (xxx)	(TR62ID) (xxxxx)
63. (TR63DT) (mm/dd/yyyy) <u>Calendar</u>	(TR63TM) (xxx)	(TR63ID) (xxxxx)
64. (TR64DT) (mm/dd/yyyy) Calendar	(TR64TM) (xxx)	(TR64ID) (xxxxx)
65. (TR65DT) (mm/dd/yyyy) Calendar	(TR65TM) (xxx)	(TR65ID) (xxxxx)
66. (TR66DT) (mm/dd/yyyy) <u>Calendar</u>	(TR66TM) (xxx)	(TR66ID) (xxxxx)
67. (TR67DT) (mm/dd/yyyy) Calendar	(TR67TM) (xxx)	(TR67ID) (xxxxx)
68. (TR68DT) (mm/dd/yyyy) Calendar	(TR68TM) (xxx)	(TR68ID) (xxxxx)

69. (TR69DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR69TM) (xxx)	(TR69ID) (XXXXX)
70. (TR70DT)	(mm/dd/yyyy) <u>Calendar</u>	(TR70TM) (xxx)	(TR70ID) (XXXXX)

Comments: (TRKCOMM)

Treatment Services Review - Part 2 (TS2)

Segment (PROTSEG): Visit Number (VISNO):

D. DRUG PROBLEMS:

How many **days** in this assessment period have you:

	IN	оит	OUT	Ουτ
1. been in in patient treatment for a drug problem?	(TSDTII) (xxx)	(TSDTIO) (XXX)	(TSDTIO2) (xxx)	(TSDTIO 3) (xxx)
a. Location of OUT service:		(TSDTIOL)	(TSDTIOL2)	(TSDTIOL3)
2. received medication to help you detoxify/come off a drug?	(TSDDM I) (xxx)	(TSDDMO) (XXX)	(TSDDMO2) (xxx)	(TSDDMO3) (xxx)
a. Location of OUT service:		(TS DDM OL)	(TSDDMOL2)	(TSDDMOL3)
3. received medication to maintain/stabilize your drug use?	(TSDMDI) (xxx)	(TSDMDO) (XXX)	(TSDMDO2) (xxx)	(TSDMDO3) (xxx)
a. Location of OUT service:		(TSDMDOL)	(TSDM DO L2)	(TSDMDOL3)
4. received medication to block the effects of drugs?	(TSDBDI) (xxx)	(TSDBDO) (xxx)	(TSDBD02) (xxx)	(TSDBD03) (xxx)
a. Location of OUT service:		(TSDBDOL)	(TSDBDOL2)	(TSDBDOL 3)
5. received a urinalysis or other test for drug use?	(TSDUAI) (xxx)	(TSDUAO) (xxx)	(TSDUA02) (xxx)	(TSDUA03) (xxx)
a. Location of OUT service:		(TSDUAOL)	(TSDUAOL2)	(TSDUAOL 3)
6. attended a drug education session?	(TSDEDI) (xxx)	(TSDEDO) (xxx)	(TSDED02) (xxx)	(TSDED03) (xxx)
a. Location of OUT service:		(TSDGEDOL)	(TSDEDOL2)	(TSDEDOL 3)
7. attended a session of NA or CA?	(TSNCSI) (xxx)	(TSNCSO) (xxx)	(TSNCSO2) (xxx)	(TSNCSO3) (xxx)
a. Location of OUT service:		(TSNCSOL)	(TSNCSOL2)	(TSNCSOL 3)

Web Version: 1.0; 3.00; 02-27-12

8. attended a drug relapse prevention group or session?	(TSDPGI) (xxx)	(TSDPGO) (xxx)	(TSDPG 02) (xxx)	(TSDPG 03) (xxx)
a. Location of OUT service:		(TSDPGOL)	(TSDPG 0L2)	(TSDPG OL3)
9. attended an individual session where there was a significant discussion regarding your drug problem(s)?	(TSDSII) (xxx)	(TSDS10) (xxx)	(TSDSI02) (xxx)	(TSDSI03) (xxx)
a. Location of OUT service:		(TSDSIOL)	(TSDSIOL2)	(TSDSIOL3)
10. attended a general group session where there was a significant discussion regarding your drug problem(s)?	(TSDSGI) (xxx)	(TSDSGO) (XXX)	(TSDSG 02) (xxx)	(TSDSG 03) (xxx)
a. Location of OUT service:		(TSDSGOL)	(TSDSG OL2)	(TSDSG OL3)

E. LEGAL PROBLEMS

How many days in this assessment period have you:	
1. been incarcerated? (TSJAIL)	(xxx)
2. engaged in illegal activities for profit?(TSILLEGL)	$(\mathbf{x}\mathbf{x}\mathbf{x})$

		(1000)		
	IN	ОИТ	OUT	OUT
3. the courts, criminal justice system, probation/parole office been contacted regarding your legal problem (either by patient or program)?	(TSCCLI) (xxx)	(TSCCLO) (xxx)	(TSCCL02) (xxx)	(TSCCLO3) (xxx)
a. Location of OUT service:		(TSCCLOL)	(TSCCLOL2)	(TSCCLOL3)
4. attended an individual session where there was a significant discussion regarding your legal problem(s)?	(TSLSII) (xxx)	(TSLS10) (xxx)	(TSLSI02) (xxx)	(TSLSIO3) (xxx)
a. Location of OUT service:		(TSLSIOL)	(TSLSIOL2)	(TSLSIOL3)
5. attended a general group session where there was a significant discussion regarding your legal problem(s)?	(TSLSGI) (xxx)	(TSLS GO) (xxx)	(TSLSG02) (xxx)	(TSLSGO 3) (xxx)
a. Location of OUT service:		(TSLS GOL)	(TSLSGOL2)	(TSLSGOL3)

F. FAMILY PROBLEMS

How many **days** in this assessment period have you:

1. experienced significant family/social problems?(TSFAMPRB)
--

2. experienced significant loneliness and/or boredom?(TSLONELY)

enced significant loneliness and/or boredom?(TSLONELY)			(X)	xx)	
	IN	OUT		OUT	оит

(xxx)

3. had a significant discussion pertinent to your family problems with family present: Family specialist?	(TSFSFI) (xxx)	(TSFSFO) (xxx)	(TSFSF02) (xxx)	(TSFSF03) (xxx)
a. Location of OUT service:		(TSFSFOL)	(TSFSF0L2)	(TSFSF0L3)
4. had a significant discussion pertinent to your family problems with family present: Counselor/social worker?	(TSFCFI) (xxx)	(TSFCFO) (xxx)	(TSFCF02) (xxx)	(TSFCF03) (xxx)
a. Location of OUT service:		(TSFCFOL)	(TSFCF0L2)	(TSFCFOL3)
5. attended an individual session where there was a significant discussion regarding your family problem(s)?	(TSFSII) (xxx)	(TSFSIO) (xxx)	(TSFS102) (xxx)	(TSFSI03) (xxx)
a. Location of OUT service:		(TSFSIOL)	(TSFSIOL2)	(TSFSIOL3)
6. attended a general group session where there was a significant discussion regarding your family problem(s)?	(TSFSGI) (xxx)	(TSFSG 0) (XXX)	(TSFSG02) (xxx)	(TSFSG 03) (xxx)
a. Location of OUT service:		(TSFSGOL)	(TSFSGOL2)	(TSFSG OL3)

G. PSYCHOLOGICAL/EMOTIONAL PROBLEMS:

How many **days** in this assessment period have you:

1. experienced significant emotional problems	s? (TSEMOTNL))		
	IN	OUT	Ουτ	OUT
2. been hospitalized for an emotional or psychological problem?	(TSHPEI) (xxx)	(TSHPEO) (XXX)	(TSHPE 02) (xxx)	(TSHPEO3) (xxx)
a. Location of OUT service:		(TSHPEOL)	(TSHPE OL2)	(TSHPEOL3)
3. received medication for your psychological or emotional problems?	(TSM DE I) (xxx)	(TSMDEO) (xxx)	(TSMDE 02) (xxx)	(TSMDEO3) (XXX)
a. Location of OUT service:		(TSMDEOL)	(TSM DE OL2)	(TSMDEOL3)
4. received testing for psychological or emotional problems?	(TSTPEI) (xxx)	(TSTPEO) (xxx)	(TSTPE02) (xxx)	(TSTPEO 3) (xxx)
a. Location of OUT service:		(TSTPEOL)	(TSTPEOL2)	(TSTSEOL3)
5. received a session in which you practiced a form of relaxation training, biofeedback, or meditation: Psych specialist?	(TSRPSI) (xxx)	(TSRPSO) (xxx)	(TSRPS 02) (xxx)	(TSRPSO3) (xxx)
a. Location of OUT service:		(TSRPSOL)	(TSRPS OL2)	(TSRPSOL3)

1	1			
6. received a session in which you practiced a form of relaxation training, biofeedback, or meditation: Counselor/social worker?	(TSRCI) (xxx)	(TSRCO) (xxx)	(TSRC02) (xxx)	(TSRC03) (xxx)
a. Location of OUT service:		(TSRCOL)	(TSRCOL2)	(TSRCOL3)
7. received a session in which you practiced a form of behavior modification (e.g., role play, rehearsal, psychodrama, etc.): Psych specialist?	(TSBHPI) (xxx)	(TSBHPO) (xxx)	(TSBHP O2) (xxx)	(TSBHPO3) (xxx)
a. Location of OUT service:		(TSBHPOL)	(TSBHP OL2)	(TSBHPOL3)
8. received a session in which you practiced a form of behavior modification (e.g., role play, rehearsal, psychodrama, etc.): Counselor/social worker?	(TSBHCI) (xxx)	(TSBHCO) (xxx)	(TSBHC02) (xxx)	(TSBHCO3) (xxx)
a. Location of OUT service:		(TSBHCOL)	(TSBHCOL2)	(TSBHCOL3)
9. had a significant discussion pertinent to your psychological or emotional problems: Psych specialist?	(TSPSII) (xxx)	(TSPSIO) (xxx)	(TSPSIO2) (xxx)	(TSPSIO 3) (xxx)
a. Location of OUT service:		(TSPSIOL)	(TSPSIOL2)	(TSPSIOL3)
10. attended a general group session where there was a significant discussion regarding your psychological or emotional problem(s)?	(TSPSGI) (xxx)	(TSPSG 0) (xxx)	(TSPSG02) (xxx)	(TSPSGO3) (xxx)
a. Location of OUT service:		(TSPSG OL)	(TSPSGOL2)	(TSPSGOL3)

H. CHILD PROTECTIVE SERVICES PROBLEMS

1. Are you active, or have an open case with child protective services?(TSOPNCPS)

🗌 No 🗌 Yes

How many **days** in this assessment period have you:

	IN	OUT	OUT	оит
2. attended an individual session where there was a significant discussion regarding your child protective services problem(s)?	(TSCPII) (xxx)	(TSCPIO) (xxx)	(TSCP102) (xxx)	(TSCPIO3) (xxx)
a. Location of OUT service:		(TSCPIOL)	(TSCPIOL2)	(TSCPIOL3)
3. attended a general group session where there was a significant discussion regarding your child protective services problem(s)?	(TSCPGI) (xxx)	(TSCPG O) (xxx)	(TSCPG02) (xxx)	(TSCPG 03) (xxx)
a. Location of OUT service:		(TSCPG OL)	(TSCPGOL2)	(TSCPG OL3)

Comments:(TSRCOMM)



NIDA Clinical Trials Network

Treatment Services Review (TSR)

(xxx)

Web Version: 1.0; 3.00; 06-07-12

Segment (*PROTSEG*): Visit Number (*VISNO*):

Date of assessment: (TSASMDT)		(mm/dd/yyyy) Click here to view calendar
Beginning of assessment period:(TSBEGDT)		(mm/dd/yyyy)
End of assessment period:(TSENDDT)		(mm/dd/yyyy) Click here to view calendar
Number of days in the assessment period:(TSDA YSPD)	(XX	x)

Please record services as (IN) separately from those provided by other sources (OUT) as specified in your local SOP.

A. MEDICAL PROBLEMS:

How many **days** in this assessment period have you:

1. experienced significant physical medical problems?(TSEXPPHY)

	IN	OUT	оит	OUT
2. been in the ED for physical medical problems?	(TSEDIN) (xxx)	(TSEDOT) (xxx)	(TSEDOT2) (xxx)	(TSED0 T3) (xxx)
a. Location of OUT service:		(TSEDOTL)	(TSEDOTL2)	(TSEDOTL3)
3. been hospitalized as an inpatient for physical medical problems?	(TSHPIN) (xxx)	(TSHPOT) (xxx)	(TSHPOT2) (xxx)	(TSHPO T3) (xxx)
a. Location of OUT service:		(TSHPOTL)	(TSHPOTL2)	(TSHPOTL3)
4. received medication for a medical problem?	(TSMDIN) (xxx)	(TSMDOT) (xxx)	(TSMDOT2) (xxx)	(TSMD0T3) (xxx)
a. Location of OUT service:		(TSMDOTL)	(TSMDOTL2)	(TSMD0TL3)
5. ma de any outpa tient visits to any healthcare provider?	(TSOPIN) (xxx)	(TS OPO T) (xxx)	(TS OPO T2) (xxx)	(TSOPOT3) (xxx)
a. Location of OUT service:		(TS OPO TL)	(TS OPO TL2)	(TSOPOTL3)
6. attended an individual session where there was a significant discussion regarding your medical problem(s)?	(TSMIDI)	(TSMIDO) (xxx)	(TSMIDO2) (xxx)	(TSMIDO3) (xxx)
a. Location of OUT service:		(TSMIDOL)	(TSMIDOL2)	(TSMIDOL 3)

7. attended a general group session where there was a significant discussion regarding your medical problem(s)?	(TSMGPI) (xxx)	(TSMGPO) (xxx)	(TSMGP 02) (xxx)	(TSMGPO3) (xxx)
a. Location of OUT service:		(TSMGPOL)	(TSMGP OL2)	(TSMGPOL3)

B. EMPLOYMENT AND SUPPORT PROBLEMS:

How many **days** in this assessment period have you:

1. been paid for working?(TSPAIDWK)

a. amount paid per day:(TSAMNTPD)

(xxx)
\$ (xxx)
(xxx)

2. been in school or training?(TSSCHTRN)

	IN	ουτ	OUT	оит
3. seen someone regarding employment opportunities, training, or education: Employment specialist?	(TSEMPI) (xxx)	(TSEMPO) (xxx)	(TSEMPO2) (xxx)	(TSEMPO3) (xxx)
a. Location of OUT service:		(TSEMPOL)	(TSEMPOL2)	(TSEMPOL3)
4. seen someone regarding employment opportunities, training, or education: Counselor/social worker?	(TSCONI) (xxx)	(TSCONO) (xxx)	(TSCONO2) (xxx)	(TSCONO3) (xxx)
a. Location of OUT service:		(TSCONOL)	(TSCONOL2)	(TSCONOL 3)
5. seen someone regarding unemployment compensation, welfare, social security, housing, or other income: Benefits specialist?	(TSBNFI) (xxx)	(TSBNFO) (xxx)	(TSBNFO2) (xxx)	(TSBNF03) (xxx)
a. Location of OUT service:		(TSBNFOL)	(TSBNFOL2)	(TSBNFOL3)
6. seen someone regarding unemployment compensation, welfare, social security, housing, or other income: Counselor/social worker?	(TSUNEI) (xxx)	(TSUNEO) (xxx)	(TSUNEO2) (xxx)	(TSUNEO3) (xxx)
a. Location of OUT service:		(TSUNEOL)	(TSUNEOL2)	(TSUNEOL 3)
7. attended an individual session where there was a significant discussion regarding your employment or support problem(s)?	(TSEMII) (xxx)	(TSEMIO) (xxx)	(TSEMI02) (xxx)	(TSEMIO3) (xxx)
a. Location of OUT service:		(TSEMIOL)	(TSEMIOL2)	(TSEMIOL3)
8. attended a general group session where there was a significant discussion regarding your employment or support problem(s)?	(TSEMGI) (xxx)	(TSEMGO) (xxx)	(TSEMGO2) (xxx)	(TSEMGO3) (xxx)

a. Location of OUT service:	(TSEM GOL)	(TSEMGOL2)	(TSEM GOL 3)

C. ALCOHOL PROBLEMS:

How many **days** in this assessment period have you:

	IN	OUT	OUT	OUT
1. been in inpatient treatment for an alcohol problem?	(TSATII) (xxx)	(TSA TIO) (xxx)	(TSA TIO2) (xxx)	(TSATIO3) (xxx)
a. Location of OUT service:		(TSATIOL)	(TSATIOL2)	(TSATIOL3)
2. received medication to help you detoxify from alcohol?	(TSADMI) (xxx)	(TSADMO) (xxx)	(TSADM 02) (xxx)	(TSADM 03) (xxx)
a. Location of OUT service:		(TSADM OL)	(TSADM OL2)	(TSADM OL3)
3. received medication to prevent you from drinking?	(TSMPDI) (xxx)	(TSMPDO) (xxx)	(TSMPD02) (xxx)	(TSMPD03) (xxx)
a. Location of OUT service:		(TSMPDOL)	(TSMPDOL2)	(TSMPDOL3)
4. received a blood a loo hol test (e.g., breathalyzer)?	(TSBATI) (xxx)	(TSBATO) (xxx)	(TSBATO2) (xxx)	(TSBA TO 3) (xxx)
a. Location of OUT service:		(TSBATOL)	(TSBATOL2)	(TSBATOL3)
5. attended an alcohol education session?	(TSAEDI) (xxx)	(TSAEDO) (xxx)	(TSAED02) (xxx)	(TSAEDO 3) (xxx)
a. Location of OUT service:		(TSAEDOL)	(TSAEDOL2)	(TSAEDOL3)
6. attended an AA or 12-step meeting?	(TSAAMI) (xxx)	(TSAAMO) (xxx)	(TSAAMO2) (xxx)	(TSAAMO3) (xxx)
a. Location of OUT service:		(TSAAMOL)	(TSAAMOL2)	(TSAAMOL3)
7. attended an alcohol relapse prevention meeting?	(TSAPMI) (xxx)	(TSAPMO) (xxx)	(TSAPMO2) (xxx)	(TSAPMO3) (xxx)
a. Location of OUT service:		(TSAPMOL)	(TSAPMOL2)	(TSAPMOL3)
8. attended an individual session where there was a significant discussion regarding your alcohol problem(s)?	(TSASII)	(TSASIO) (xxx)	(TSASIO2) (xxx)	(TSASIO 3) (xxx)
a. Location of OUT service:		(TSASIOL)	(TSA SIO L2)	(TSAS IOL3)
9. attended a general group session where there was a	(TSASGI)	(TSASGO) (xxx)	(TSASG02) (xxx)	(TSASG03) (xxx)

significant discussion regarding your alcohol problem(s)?	(<i>xxx</i>)			
a. Location of OUT service:		(TSASGOL)	(TSASGOL2)	(TSASGOL3)

NIDA Clinical Trials Network				
Working Alliance Inventor	ry - Short Form - Revised (WAI)			
Segment <i>(PROTSEG)</i> : Visit Number <i>(VISNO</i>):	Web Version: 1.0; 1.01; 10-26-10			
Date of assessment: (WAASMDT) Instructions: Below is a series of statements about experiences people might have with their therapy or therap	rticipant RA who did not serve as interventionist (mm/dd/yyyy) Click here to view calendar vist. Some items refer directly to your therapist with an underlined space as you read the sentences, mentally insert the ur own experience and then fill in the appropriate checkbox. Important: The rating scale is not the same for all the			
(WACHANGE) Seldom Sometimes Fairly Often Very Often Always 2. This counseling session gave me new ways of looking at my problem. (WANWLOOK) Seldom Sometimes Fairly Often Very Often Always				
 3. I believe likes me. (WALIKE) Always Very Often Fairly Often Sometimes Seldom 4 and I collaborated on setting goals for my counseling session. (WACOLBRT) Seldom Sometimes Fairly Often Very Often Always 5 and I respect each other. 				
(WARESPCT) Always Very Often Fairly Often Sometimes Seldom 6. and I worked towards mutually agreed upon goals. (WAGOALS) Always Very Often Fairly Often Sometimes Seldom				
 7. I feel that appreciates me. (WAAPPRCT) Always Very Often Fairly Often Sometimes Seldom 8 and I agreed on what is important for me to work on. (WAIMPT) Seldom Sometimes Fairly Often Very Often Always 				
 9. I feel cares about me even if I do things that he/she does not approve of. (WACARES) Always Very Often Fairly Often Sometimes Seldom 10. I felt that the things I did in this counseling session will help me to accomplish the changes that I want. 				
(WAACMPLH) Seldom Sometimes Fairly Often Very Often Aways 11 and lestablished a good understanding of the kind of changes that would be good for me. (WAGDCHGS) Seldom Sometimes Fairly Often Very Often Always				
12. I believe the way we worked with my problem is correct. (WAPRBLM) Always Very Often Fairly Often Sometimes Seldom				